S&P BSE Dollex 30 News and Updates

Name: Latest research reports of Coal India Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Coal India Ltd.
Rating: 3
Author: Geojit BNP Paribas

Keep track of all breaking news on S&P BSE Dollex 30 from all sources in a single place.

Load latest

Maruti Suzuki India Ltd.

28 Aug 2025

15324.00

1.52%

Will e-Vitara launch drive gains for Maruti Suzuki stock? Strategy decoded

Business Standard

Maruti Suzuki launches its first EV SUV, e-Vitara, with global export focus. Analysts decode stock outlook, price targets, and growth strategy

Maruti Suzuki India Ltd. has gained 31.57% in the last 6 Months

HDFC Bank Ltd.

28 Aug 2025

968.65

0.09%

HDFC Bank shares dip 2% after 1.56 million shares change hands in block deal after bonus adjustment

Economic Times

A large block deal of 1.56 million HDFC bank shares was executed just a day after the bank's stock price adjusted for its recent 1:1 bonus issue, which took effect on Tuesday. Block deals are bulk trades between big investors, executed via a separate window to avoid adding volatility to regular market trading.

Number of FII/FPI investors increased from 3827 to 3962 in Jun 2025 qtr.

HDFC Bank emerges as top choice for global EM funds with record ownership

Business Standard | 28 Aug 2025

Adani Ports & Special Economic Zone Ltd.

28 Aug 2025

1396.30

0.23%

Adani Portfolio Q1 Review: EBITDA Hits All-Time High; Ambuja Cement, Adani Ports Among Growth Drivers

NDTV Profit

Adani Portfolio Q1 Review: Key contributors to growth included businesses like Airports, as well as Adani Green Energy, Adani Energy Solutions, Adani Ports & SEZ, and Ambuja Cements.

Motilal Oswal released a Buy report for Adani Ports & Special Economic Zone Ltd. with a price target of 1700.0 on 26 Aug, 2025.

Coal India Ltd.

28 Aug 2025

394.20

0.22%

COAL INDIA LIMITED

Hold: Coal India Ltd.

Target

Geojit BNP Paribas

Coal India Ltd (CIL) is one of the largest coal producer in the world, with its output totalling 781 million tonnes (MT) in FY2025. It aims to increase coal production to 1 billion tonnes by FY2028-29. The company has 14 fully owned subsidiary companies...

Coal India Ltd. is trading above all available SMAs

Cipla Ltd.

27 Aug 2025

1572.70

0.76%

Cipla Recalls Over 20,000 Packs Of Inhalation Drug In US

NDTV Profit

The company is recalling 20,352 packs of the inhalation drug due to 'Failed Stability Specifications

Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.

Cipla recalls over 20k packs of inhalation drug in US

Business Line | 27 Aug 2025

Tata Steel Ltd.

26 Aug 2025

168.99

-0.25%

Tata Steel Acquires Shares Worth Rs 3,104 Crore In Singapore Unit

NDTV Profit

The latest stake acquisition comes after Tata Steel had acquired a stake worth Rs 1,074 crore in T Steel Holdings in July.

Tata Steel Ltd. has an average target of 165.43 from 7 brokers.

Maruti Suzuki India Ltd.

26 Aug 2025

15324.00

1.52%

No 'Protection' Needed From Trump Tariffs Impact: Maruti Suzuki's RC Bhargava

NDTV Profit

Domestic sales are yet to be announced and till that time, all production will be directed towards exports, says the chairperson.

Maruti Suzuki India Ltd. has gained 21.65% in the last 1 Month

Suzuki Motor To Invest Rs 70,000 Crore In India Over Next 5-6 years: Toshihiro Suzuki

NDTV Profit | 26 Aug 2025 1 more

Dr. Reddy's Laboratories Ltd.

26 Aug 2025

1317.00

1.07%

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Business Standard

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr Reddy's launches drug for treatment of chronic constipation

Business Line | 26 Aug 2025 1 more

Tata Consultancy Services Ltd.

26 Aug 2025

3130.50

0.20%

TCS forms new AI and services transformation unit, Amit Kapur to lead

Business Standard

TCS has created a new AI and Services Transformation Unit under Amit Kapur, consolidating its AI strategy and accelerating innovation, client engagement, and digital transformation